In collaboration with prominent academic institutions (Aarhus University, CIC bioGUNE, Parc de Recerca Biomèdica and Molecular Immunology Unit, Hospital Universitario Puerta de Hierro), LeadArtis´scientists have developed a new approach to generate mono and multispecific antibodies by fusing single-domain antibodies from camelid heavy-chain-only immunoglobulins (VHHs) to the human collagen XVIII trimerization domain (TIEXVIII).

The second IACT assessment meeting took place during November 20-21, 2015 in Pamplona, Spain. LeadArtis is a partner of the Immunostimulatory Agonist Antibodies for Cancer Therapy, a 6.9M€ funding consortium which incorporates long-standing expertise in agonist immunostimulatory antibodies (IS-Abs) from research institutions and small-medium enterprises (SEM) in five European countries (Germany, Italy, Spain, Sweden and United Kingdom).

Trimerbody^® is a unique mono/multispecific antibody format based on the use of specific collagen trimerization domains and optimized peptide linkers. Trimerbodies are trimeric in solution and exhibit excellent antigen binding capacity and stability in vitro and in vivo.

Leadartis is proud to announce its participation as a partner in the TERET project (New Treatments for Degenerative Retina Diseases) funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS of the society program. The MINECO’s participation demonstrates its support of Leadartis technology research and main objectives.